RLYB Rallybio Corp

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

$7.55
As of 06/30/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/29/2021
Outstanding shares:  32,130,970
Average volume:  142,542
Market cap:   $234,556,081
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMGTPL0
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.39
PS ratio:   0.00
Return on equity:   -29.59%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy